Skip to main content
    C

    Caris Life Sciences, Inc. Common Stock (CAI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.00
    -2.04 (-8.85%)

    Market Cap: $6.61B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Caris Life Sciences, Inc. Common Stock (CAI) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Caris Life Sciences, Inc. Common Stock are Ionis Pharmaceuticals (IONS), Axsome Therapeutics (AXSM) and Kodiak Sciences (KOD). By market cap, Caris Life Sciences, Inc. Common Stock ranks 7th of the 13 companies on this page; Cytokinetics (CYTK) is the largest at $7.82B.

    Peer Comparison

    CAI's revenue growth of 27.0% is above the peer median of 25.9%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Caris Life Sciences, Inc. Common Stock (CAI)$6.61BN/A5.7x9.2%N/A27.0%0.00%
    Ionis Pharmaceuticals Inc (IONS)$4.84BN/A4.8x-56.9%-29.3%54.9%0.00%
    Axsome Therapeutics Inc (AXSM)$7.45BN/A8.6x-18.2%-48.1%51.9%0.00%
    Kodiak Sciences Inc (KOD)$7.27BN/AN/A0.0%-1481.8%0.0%0.00%
    Cytokinetics Inc (CYTK)$7.82BN/A65.3x0.0%-66.0%2357.0%0.00%
    Iovance Biotherapeutics Inc (IOVA)$3.59BN/A9.1x-58.2%N/A80.1%0.00%
    CG Oncology, Inc. Common stock (CGON)$6.65BN/AN/A0.0%-21.1%-3.7%0.00%
    Abivax SA American Depositary Shares (ABVX)$7.67BN/AN/A0.0%-159.6%-6.8%0.00%
    Cogent Biosciences Inc (COGT)$4.97BN/AN/A0.0%-43.4%-100.0%0.00%
    Crispr Therapeutics AG (CRSP)$4.10BN/A155.2x0.0%-20.3%1325.0%0.00%
    Erasca Inc (ERAS)$5.50BN/AN/A0.0%N/A0.0%0.00%
    Immunovant Inc (IMVT)$7.07BN/AN/A0.0%N/A0.0%0.00%
    Tarsus Pharmaceuticals Inc (TARS)$3.96BN/A5.4x-102.9%-393.6%63.9%0.00%
    Peer median$6.07BN/A8.8x0.0%-48.1%25.9%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Caris Life Sciences, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ionis Pharmaceuticals Inc (IONS)
    Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
    IONS competitors
    Axsome Therapeutics Inc (AXSM)
    Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United...
    AXSM competitors
    Kodiak Sciences Inc (KOD)
    Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing...
    KOD competitors
    Cytokinetics Inc (CYTK)
    Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering...
    CYTK competitors
    Iovance Biotherapeutics Inc (IOVA)
    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness...
    IOVA competitors
    CG Oncology, Inc. Common stock (CGON)
    CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070...
    CGON competitors
    Abivax SA American Depositary Shares (ABVX)
    Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections.
    ABVX competitors
    Cogent Biosciences Inc (COGT)
    Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases.
    COGT competitors
    Crispr Therapeutics AG (CRSP)
    CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases.
    CRSP competitors
    Erasca Inc (ERAS)
    Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers...
    ERAS competitors
    Immunovant Inc (IMVT)
    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
    IMVT competitors
    Tarsus Pharmaceuticals Inc (TARS)
    Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates...
    TARS competitors

    Frequently Asked Questions About CAI

    Who are Caris Life Sciences, Inc. Common Stock's main competitors?

    The companies most similar to Caris Life Sciences, Inc. Common Stock include Ionis Pharmaceuticals (IONS), Axsome Therapeutics (AXSM), Kodiak Sciences (KOD), Cytokinetics (CYTK) and Iovance Biotherapeutics (IOVA), listed from the closest match.

    Who is Caris Life Sciences, Inc. Common Stock's biggest competitor?

    Cytokinetics (CYTK) is the largest of the similar companies at $7.82B; Ionis Pharmaceuticals (IONS) is the closest match by business profile, size, sector and industry.

    How does CAI stock compare with its competitors?

    CAI's P/S is 5.7x against a peer median of 8.8x; its net margin is 9.2% against a peer median of 0.0%.

    Which of Caris Life Sciences, Inc. Common Stock's competitors pays a higher dividend?

    Caris Life Sciences, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Caris Life Sciences, Inc. Common Stock bigger than its competitors?

    No. Caris Life Sciences, Inc. Common Stock is 7th by market cap among the 13 companies on this page; the largest is Cytokinetics (CYTK) at $7.82B.